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Plasma neurofilament light chain and
amyloid-β are associated with the
kynurenine pathway metabolites in
preclinical Alzheimer’s disease
Pratishtha Chatterjee1,2, Henrik Zetterberg3,4,5,6, Kathryn Goozee1,2,7,8,9, Chai K. Lim1, Kelly R. Jacobs1,
Nicholas J. Ashton3,10,11,12, Abdul Hye10,11, Steve Pedrini2, Hamid R. Sohrabi1,2,7,13, Tejal Shah1,2,13, Prita R. Asih1,
Preeti Dave1,8, Kaikai Shen14, Kevin Taddei2,13, David B. Lovejoy1, Gilles J. Guillemin1†, Kaj Blennow3,4† and
Ralph N. Martins1,2,7,9,13,15,16*†

Abstract
Background: Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer’s disease
amyloid pathology (amyloid-β; Aβ), and neuroinflammation (kynurenine pathway; KP metabolites) have been
investigated independently in neurodegenerative diseases. However, the association of these markers of
neurodegeneration and AD pathology with neuroinflammation has not been investigated previously. Therefore, the
current study examined whether NFL and Aβ correlate with KP metabolites in elderly individuals to provide insight
on the association between blood indicators of neurodegeneration and neuroinflammation.
Methods: Correlations between KP metabolites, measured using liquid chromatography and gas chromatography
coupled with mass spectrometry, and plasma NFL and Aβ concentrations, measured using single molecule array
(Simoa) assays, were investigated in elderly individuals aged 65–90 years, with normal global cognition (Mini-Mental
State Examination Score ≥ 26) from the Kerr Anglican Retirement Village Initiative in Ageing Health cohort.
Results: A positive correlation between NFL and the kynurenine to tryptophan ratio (K/T) reflecting indoleamine 2,
3-dioxygenase activity was observed (r = .451, p < .0001). Positive correlations were also observed between NFL and
kynurenine (r = .364, p < .0005), kynurenic acid (r = .384, p < .0001), 3-hydroxykynurenine (r = .246, p = .014),
anthranilic acid (r = .311, p = .002), and quinolinic acid (r = .296, p = .003). Further, significant associations were
observed between plasma Aβ40 and the K/T (r = .375, p < .0005), kynurenine (r = .374, p < .0005), kynurenic acid
(r = .352, p < .0005), anthranilic acid (r = .381, p < .0005), and quinolinic acid (r = .352, p < .0005). Significant
associations were also observed between plasma Aβ42 and the K/T ratio (r = .215, p = .034), kynurenic acid (r = .214,
p = .035), anthranilic acid (r = .278, p = .006), and quinolinic acid (r = .224, p = .027) in the cohort. On stratifying
participants based on their neocortical Aβ load (NAL) status, NFL correlated with KP metabolites irrespective of NAL
status; however, associations between plasma Aβ and KP metabolites were only pronounced in individuals with
high NAL while associations in individuals with low NAL were nearly absent.
(Continued on next page)
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Conclusions: The current study shows that KP metabolite changes are associated with biomarker evidence of
neurodegeneration. Additionally, the association between KP metabolites and plasma Aβ seems to be NAL status
dependent. Finally, the current study suggests that an association between neurodegeneration and
neuroinflammation manifests in the periphery, suggesting that preventing cytoskeleton cytotoxicity by KP
metabolites may have therapeutic potential.
Keywords: Blood markers, Neuroinflammation, Neurodegeneration, Alzheimer’s disease, Neurofilament light chain,
Amyloid-beta, Kynurenine pathway, Brain amyloid-beta, Blood amyloid-beta

Introduction
Neurofilament light chain (NFL), an axonal cytoskeletal
protein, is an emerging blood marker for neurodegenerative diseases, for review see [1]. Since neurodegenerative
processes involve axonal damage resulting in the release
of neuronal NFL into extracellular spaces with subsequent
diffusion into the cerebrospinal fluid (CSF) and the blood,
elevated CSF and blood NFL concentrations are now
recognised as features of several neurodegenerative diseases [2–7], including Alzheimer’s disease (AD) [8].
Neurodegeneration is known to be associated with
neuroinflammation [9], and the kynurenine pathway
(KP) is strongly upregulated in neuroinflammatory
conditions [10–13]. The KP is induced by the activation
of the enzyme, indoleamine 2,3-dioxygenase (IDO1),
resulting in the metabolism of tryptophan (TRP) to kynurenine (KYN). Following the formation of KYN, the enzyme kynurenine aminotransferase converts KYN to

kynurenic acid (KA). Alternatively, the enzymes kynureninase and kynurenine 3-monooxygenase metabolise KYN
to anthranilic acid (AA) and 3-hydroxykynurenine (3HK), respectively. Further, AA and 3-HK get metabolised to 3-hydroxyanthranilic acid (3-HAA), which
further converts to aminocarboxymuconic semialdehyde (ACMA). ACMA either generates picolinic acid
(PA) via the enzyme 2-amino-3-carboxymuconatesemialdehyde decarboxylase or spontaneously gets converted to quinolinic acid (QA), a neurotoxin and
precursor for the redox agent, nicotinamide adenine
dinucleotide (Fig. 1) [14]. Several inflammatory molecules such as interferon-γ, tumour necrosis factor-α,
toll-like receptor 4, and lipopolysaccharide activate
IDO1 triggering the production of several neuroactive
KP metabolites by most of the brain cells, i.e.
microglia, astrocytes, neurons, and infiltrating macrophages [15].

Fig. 1 The kynurenine pathway schematic. Within the KP, tryptophan is metabolised to kynurenine (KYN) via the enzymes indoleamine 2,3deoxygenase or tryptophan deoxygenase and formamidase. KYN gets converted to kynurenic acid (KA) via the enzyme kynurenine
aminotransferase. KYN is also metabolised to anthranilic acid (AA) by the enzyme kynureninase and to 3-hydroxykynurenine (3-HK) by the enzyme
kynurenine-3-monooxygenase. AA and 3-HK are metabolised to 3-hydroxyanthranilic acid (3-HAA). 3-HAA further converts to
aminocarboxymuconic semialdehyde that spontaneously either converts to the neurotoxin, quinolinic acid, a substrate for the redox agent, NAD+
or is assisted by enzyme 2-amino-3-carboxymuconatesemialdehyde decarboxylase to generate picolinic acid

Chatterjee et al. Journal of Neuroinflammation

(2019) 16:186

Page 3 of 12

Increasing evidence shows that the KP is triggered in
several neurodegenerative diseases [10, 16–19]. Further,
several studies including those from our laboratory also
report associations between the KP metabolites and AD
pathogenesis, from the preclinical stage prior to cognitive
decline to the clinical stage [14, 20–23]. For instance,
higher plasma KYN to TRP (K/T) ratios, reflecting higher
IDO activity, have been observed within the different
stages of AD pathogenesis [14, 24, 25]. Two relatively recent studies observed elevated plasma AA concentrations
in preclinical AD and in individuals at risk to dementia
[14, 26]. Additionally, a decline in serum KA [27] and increase in plasma QA [28] have been observed in individuals with mild cognitive impairment (MCI) and AD.
While NFL and the KP have both independently been
reported to be associated with neurodegenerative diseases as described above, the association between the
neurodegenerative marker, NFL, and markers indicative
of neuroinflammation, such as KP metabolites, has not
been investigated previously. The current study therefore
investigated whether an association between NFL and
KP metabolites was present in cognitively normal elderly
individuals to provide insight on the association between
blood indicators of neurodegeneration and neuroinflammation. Further, the increasing emphasis of plasma
amyloid-β (Aβ) as a potential marker for AD [29, 30] led
us to also investigate the associations between KP metabolites and plasma Aβ 40 and 42 species within the
current study. Additionally, participants within the
current study were also categorised as those within the
preclinical phase of AD, characterised by high neocortical Aβ load (NAL) assessed via positron emission tomography (PET), and those with no apparent risk to AD
or low NAL, to separately evaluate the aforementioned
associations in each group (high/low NAL) in order to
assess whether these associations were specific to ADrelated neuropathology.

MoCA scores lying between 18 and 25 were assessed on a
case by case basis by the study neuropsychologist following
stratification of scores according to age and education [32].
The exclusion criteria comprised the diagnosis of dementia
based on the revised criteria from the National Institute on
Aging-Alzheimer’s Association [33], presence of acute functional psychiatric disorder (including lifetime history of
schizophrenia or bipolar disorder), history of stroke, severe
or extremely severe depression (based on the Depression
Anxiety Stress Scales), and uncontrolled hypertension (systolic BP > 170 mmHg or diastolic BP > 100 mmHg).
The 105 participants who met the eligibility criteria
underwent neuroimaging, neuropsychometric evaluation,
and blood collection, while the remaining either withdrew
or declined neuroimaging. Within these 105 participants,
100 participants were considered to have normal global
cognition based on their Mini-Mental State Examination
(a 0–30 point test used to screen cognitive impairment)
score (MMSE ≥ 26) [34] and were included in the current
study. Plasma NFL and KP concentrations were measured
in all 100 participants with MMSE ≥ 26, while plasma Aβ
40 and 42 species were measured in 98 and 97 participants
(95 common), respectively, of the 100 participants with
MMSE ≥ 26. All volunteers provided written informed
consent prior to participation, and the Bellberry Human
Research Ethics Committee, Australia (reference no.
2012-09-1086), and the Macquarie University Human Research Ethics Committee, Australia, provided approval for
the study (reference no. 5201701078).

Methods
Participants

Measurement of plasma neurofilament light chain and
amyloid-β concentrations

Participants from the Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohort, at baseline,
described previously [31], were utilised in the current study.
Briefly, 134 volunteers met the set screening eligibility inclusion and exclusion criteria for the KARVIAH cohort.
The inclusion criteria comprised an age range of 65–90
years, good general health, no known significant cerebral
vascular disease, fluent in English, adequate/corrected vision and hearing to enable testing, and no objective cognitive impairment as screened by a Montreal Cognitive
Assessment (MoCA; a 0–30 point test assessing cognitive
domains including short-term recall, learning trials, delayed
recall, visuospatial abilities, three-dimensional cube, trail
making, fluency, abstraction, and attention) score ≥ 26.

The ultra-sensitive single molecule array (Simoa, Quanterix) platform was employed to measure plasma NFL
and Aβ concentrations [8, 36, 37]. Calibrators were run
in duplicates while samples were diluted fourfold for
NFL and Aβ42, and eightfold for Aβ40 and run in singlicates. Two quality control (QC) samples were run in duplicates at the beginning and end of each plate for NFL,
wherein a QC sample with a concentration of 12.1 pg/
mL had repeatability and intermediate precision of
20.2%, while for a QC sample with a concentration of
155.8 pg/mL, repeatability was 14.6% and intermediate
precision was 14.9%. For Aβ40, a QC sample with a concentration of 219 pg/mL, repeatability was 6.9% and
intermediate precision was 7.9%. For Aβ42, a QC sample

Blood collection and APOE genotyping

All participants fasted for a minimum of 10 h overnight
prior to blood withdrawal employing standard serological methods and processing of serum and plasma
[35]. Apolipoprotein E (APOE) genotype was determined
from purified genomic DNA extracted from 0.5 mL
whole blood as previously described [35].
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with a concentration of 12.9 pg/mL, repeatability was
2.4% and intermediate precision was 5.6%.
Measurement of serum kynurenine pathway metabolites

Serum samples were collected in 2015 and stored at −
80 °C until thawed for measurement of KP metabolites in
2017. Serum kynurenine metabolites were measured as described previously [14]. Briefly, analyses of tryptophan,
KYN, 3-HK, 3-HAA, and AA were performed simultaneously with ultra-high-performance liquid chromatography
(UHPLC) [11]. KA separation was carried out following injection (10 μL) onto a Poroshell RRHT C-18, 1.8 μm 2.1 ×
100 mm column (Agilent Technologies, Inc., Santa Clara,
CA), and quantified via fluorescence detection (excitation
and emission wavelengths of 344 nm and 388 nm, respectively; retention time 1.5 min). A gradient method with 50
mM sodium acetate, 25 mM zinc acetate and 2.25% acetonitrile (eluent A), and 10% acetonitrile (eluent B) was
employed, and separation was performed at 38 °C with a
flow rate of 0.75 mL/min. Separation achieved over 10 min
comprised 100% eluent A for 3 min, 50% eluent A for 2
min, 0% eluent A for 2 min, and re-equilibration with 100%
eluent A for 3 min. Data were analysed with the Agilent
OpenLAB CDS ChemStation (Edition C.01.04).
Simultaneous analysis of picolinic acid and quinolinic
acid was performed as described previously [38] with
minor modifications using an Agilent 7890A gas chromatography (GC) system coupled with Agilent 5975 C
mass spectrometry detector and Agilent 7693A autosampler (Agilent Technologies, Inc., Santa Clara, CA) with
1 μL of derivatized mixture. Separation of picolinic acid
and quinolinic acid was achieved with a DB-5MS column, 0.25 μm film thickness, and 0.25 mm × 30 m capillary column (Agilent Technologies, Inc., Santa Clara,
CA) within 7 min, but the assay run time was set for 12
min to prevent sample carryover. Picolinic acid and quinolinic acid concentrations were analysed using Agilent
GC/MSD ChemStation software (Edition 02.02.1431)
and interpolated from the established 6-point calibration
curves based on the abundance count ratio of the metabolites to their corresponding deuterated internal standards within each standard and sample. The intra- and
inter-assay CV was within the acceptable range (4–8%
for UHPLC assays, 7–10% for GCMS assays) calculated
from the repeated measures of the metabolite standards
incorporated during the sequence run.
Neuroimaging

All study participants were imaged within 3 months of
blood collection. Participants underwent positron emission tomography (PET) using ligand 18F-florbetaben at
Macquarie Medical Imaging in Sydney. Participants were
administered an intravenous bolus of 18F-florbetaben
slowly over 30 s, while in a rested position. Images were
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acquired over a 20-min scan, in 5 min acquisitions, beginning 50 min post-injection. Neocortical amyloid-β load
was calculated as the mean standard uptake value ratio
(SUVR) of the frontal, superior parietal, lateral temporal,
lateral occipital, and anterior and posterior cingulate regions with the cerebellum as the reference region, using
image processing software CapAIBL [39, 40]. Study participants with an SUVR< 1.35 were categorised as low NAL,
while those with an SUVR ≥ 1.35 were classified as high
NAL.
Statistical analyses

Descriptive statistics including means and standard deviations were calculated for NAL− and NAL+ groups (Table 1)
and for NFL quartiles Q1 vs. Q2, Q3, and Q4 (Additional file 1: Table S1). Chi-square tests were employed to
compare the frequency of gender and APOE ε4 carrier status between NAL− and NAL+ groups, and across NFL
quartiles. Additionally, linear models were employed to
compare continuous variables examined between study
groups. Continuous response variables were tested for approximate normality and log transformed when required to
satisfy test criteria. Pearson’s correlation coefficient was
employed to investigate correlations. Partial correlations
were used when associations investigated were adjusted for
age, gender, and APOE ε4 carrier status. All analyses were
carried out using IBM® SPSS® version 23.

Results
Cohort characteristics

Cohort characteristics are presented in Table 1. The cohort was divided into low and high NAL groups or
grouped according to NFL quartiles (Additional file 1:
Table S1). On comparing the low NAL with the high
NAL group, no significant differences were observed, except for the significantly higher frequency of APOE ε4
carriers within the high NAL group, which was expected
given that carriage of the APOE ε4 allele is a known risk
factor for AD and high NAL [41]. Higher age and lower
MMSE scores were associated with higher NFL quartiles
as expected [42]. No significant differences in education
and NAL were observed between individuals categorised
based on their plasma NFL concentrations. Additionally,
no significant differences in gender or APOE ε4 carrier
status were observed between individuals lying in the
different NFL quartiles.
Correlation between NFL and KP metabolites in all
participants

NFL was observed to have a positive correlation with the
K/T ratio (r = .451, p < .0001). Positive correlations were
also observed between NFL and KP metabolites, KYN
(r = .364, p < .0005), KA (r = .384, p < .0001), 3-HK (r = .246,
p = .014), AA (r = .311, p = .002), and QA (r = .296,
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Table 1 Cohort characteristics
p

All participants

Low NAL

High NAL

Gender (N, males/females)

32/68

19/46

13/22

.419

Age (years)

78.18 ± 5.52

77.61 ± 5.55

79.22 ± 5.38

.165

APOE ε4 carriers (N, %)

21 (21)

5 (7.7)

16 (45.7)

< .0001

Education (years)

14.43 ± 3.26

14.84 ± 3.37

13.64 ± 2.91

.078

MMSE (score)

28.61 ± 1.14

28.50 ± 1.16

28.80 ± 1.10

.225

NAL (SUVR)

1.35 ± 0.31

1.15 ± 0.08

1.71 ± 0.26

–

Tryptophan (μM)

43.33 ± 7.72

42.87 ± 8.15

44.17 ± 6.87

.350

Kynurenine (μM)

2.23 ± 0.58

2.12 ± 0.52

2.41 ± 0.63

< .05

Kynurenine to tryptophan ratio (K/T)

52.61 ± 15.44

50.73 ± 13.94

56.08 ± 17.58

.121

Kynurenic Acid (nM)

52.06 ± 27.44

49.71 ± 26.25

56.41 ± 29.40

.238

3-Hydroxykynurenine (nM)

119.45 ± 37.47

117.74 ± 34.73

122.60 ± 42.42

.554

3-Hydroxyanthranilic acid (nM)

22.63 ± 9.14

22.15 ± 9.25

23.50 ± 8.99

.406

Anthranilic acid (nM)

35.48 ± 19.79

31.40 ± 14.99

43.04 ± 25.02

< .005

Picolinic acid (nM)

109.38 ± 49.82

112.06 ± 56.25

104.40 ± 35.07

.572

Quinolinic acid (nM)

171.83 ± 74.48

169.76 ± 75.89

175.66 ± 72.71

.689

Baseline characteristics including gender, age, APOE ε4 status, education, Mini-Mental State Examination (MMSE) scores, and neocortical amyloid-β load (NAL)
represented by the standard uptake value ratio (SUVR) of ligand 18F-florbetaben assessed via positron emission tomography, in the neocortical region normalised
with that in the cerebellum, have been compared between low NAL (SUVR< 1.35) and high NAL (SUVR ≥ 1.35) study participants. Chi-square tests or linear models
were employed as appropriate. Data have been presented in mean ± SD unless otherwise mentioned. Kynurenine to tryptophan ratios for all participants were
multiplied by 1000. All p values for the kynurenine pathway metabolites were obtained from variables transformed to the logarithmic scale for analyses to meet
assumptions of the statistical test employed

p = .003). Figure 2 presents correlations between NFL and
KP metabolites. After adjusting for age, gender, and APOE
ε4 status, all the above-mentioned associations between
NFL and KP metabolites, except for 3-HK, continued to remain significant (Additional file 2: Table S2).
Correlation between NFL and KP metabolites in
participants with low NAL

NFL positively correlated with the K/T ratio (r = .450,
p < .0005) in the 65 participants with low NAL. Positive
correlations were also observed between NFL and KP metabolites, KYN (r = .335, p = .006), KA (r = .348, p = .005),
and AA (r = .278, p = .025). Figure 3 presents correlations
between NFL and KP metabolites. After adjusting for age,
gender, and APOE ε4 status, the above-mentioned associations between NFL and KP metabolites continued to remain significant (Additional file 2: Table S2).
Correlation between NFL and KP metabolites in
participants with high NAL

NFL positively correlated with the K/T ratio (r = .436,
p = .009) in the 35 participants with high NAL. Positive
correlations were also observed between NFL and KP
metabolites, KYN (r = .390, p = .020), KA (r = .428,
p = .010), 3-HK (r = .411, p = .014), AA (r = .335,
p = .049), and QA (r = .411, p = .014). Figure 3 presents
correlations between NFL and KP metabolites. After
adjusting for age, gender, and APOE ε4 status, KYN and
KA remained significant (Additional file 2: Table S2).

Correlation between plasma Aβ and KP metabolites in all
participants

Plasma Aβ40 positively correlated with the K/T ratio
(r = .375, p < .0005). A positive correlation was also observed between Aβ40 and KP metabolites, KYN
(r = .374, p < .0005), KA (r = .352, p < .0005), AA
(r = .381, p < .0005), PA (r = .205, p = .042), and QA
(r = .352, p < .0005). Figure 4 presents correlations between Aβ40 and KP metabolites. After adjusting for age,
gender, and APOE ε4 status, all the above-mentioned associations between Aβ40 and KP metabolites, except for
PA, continued to remain significant (Additional file 3:
Table S3). Plasma Aβ42 positively correlated with the K/
T ratio (r = .215, p = .034), KA (r = .214, p = .035), AA
(r = .278, p = .006), and QA (r = .224, p = .027). Figure 4
presents correlations between Aβ42 and KP metabolites.
After adjusting for age, gender, and APOE ε4 status,
Aβ42 only continued to correlate significantly with KA
and AA while a trend remained for QA (Additional file 4:
Table S4). Furthermore, the plasma Aβ40/42 ratio correlated with KYN (r = .236, p = .024) after adjusting for
age, gender, and APOE ε4 status.
Correlation between plasma Aβ and KP metabolites in
participants with low NAL

Plasma Aβ40 positively correlated with AA (r = .255,
p = .044) and PA (r = .307, p = .014) while plasma Aβ42
was not observed to correlate with any KP metabolite in
low NAL (n = 63 for Aβ40, n = 65 for Aβ42) participants.
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Fig. 2 Correlations between KP metabolites and NFL in all participants. Plasma neurofilament light chain (NFL) correlated with the kynurenine to
tryptophan ratio (K/T) and other kynurenine pathway (KP) metabolites, namely kynurenine (KYN), kynurenic acid (KA), 3-hydroxykynurenine (3-HK),
anthranilic acid (AA), and quinolinic acid (QA) using Pearson’s correlation coefficient. Log transformed plasma NFL and KP analyte concentrations
have been presented

After adjusting for age, gender, and APOE ε4 status, only
PA correlated with Aβ40 (Additional file 3: Table S3).
Figure 5 presents correlations between Aβ40 and KP
metabolites. The plasma Aβ40/42 ratio correlated with
3-HK (r = .255, p = .049) after adjusting for age, gender,
and APOE ε4 status.
Correlation between plasma Aβ and KP metabolites in
participants with high NAL

Figure 6 presents correlations between Aβ42 and KP
metabolites. After adjusting for age, gender, and APOE
ε4 status, Aβ42 continued to correlate significantly with
the aforementioned metabolites while a trend was observed with the K/T ratio (Additional file 4: Table S4).
Furthermore, the plasma Aβ40/42 ratio correlated with
the K/T ratio (r = .462, p = .012) and KYN (r = .390,
p = .037) after adjusting for age, gender, and APOE ε4
status.

Plasma Aβ40 positively correlated with the K/T ratio
(r = .627, p < .0001) in participants with high NAL. A
positive correlation was also observed between Aβ40
and KP metabolites, KYN (r = .578, p < .0005), KA
(r = .503, p = .002), AA (r = .482, p = .003), and QA
(r = .615, p < .0001) (n = 35 for Aβ40). Figure 6 presents
correlations between Aβ40 and KP metabolites. After
adjusting for age, gender, and APOE ε4 status, all the
above-mentioned associations between Aβ40 and KP
metabolites continued to remain significant (Additional file 3: Table S3). Further, plasma Aβ42 positively
correlated with the K/T ratio (r = .494, p = .004), KYN
(r = .467, p = .007), KA (r = .387, p = .029), AA (r = .576,
p = .0006), and QA (r = .539, p = .001) (n = 32 for Aβ42).

Discussion
The current study investigated the association of the
KP metabolites with two emerging blood biomarkers
for AD, namely NFL and Aβ. NFL has widely been
reported to increase with the severity of neurodegeneration and cognitive impairment, including that in
AD [8, 42–44], while plasma Aβ has shown strong
potential in reflecting brain Aβ burden showing approximately 90% accuracy [29, 30].
Within the current study, significant positive associations between KP metabolites and NFL were observed.
Interestingly, the positive association between the K/T
ratio and NFL also suggests a positive association
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Fig. 3 Correlations between KP metabolites and NFL in participants with low NAL (a) and high NAL (b). Plasma neurofilament light chain (NFL)
correlated with the kynurenine to tryptophan ratio (K/T) and other kynurenine pathway (KP) metabolites, namely kynurenine (KYN), kynurenic acid
(KA), and anthranilic acid (AA) in participants with low NAL. Plasma NFL correlated with the K/T and other kynurenine pathway KP metabolites,
namely KYN, KA, AA, 3-HK, and QA. Analyses were carried out using Pearson’s correlation coefficient. Log transformed plasma NFL and KP analyte
concentrations have been presented

between IDO (the first-rate limiting enzyme of the KP)
activity and NFL. Given that increased IDO activity
has been observed in inflammatory conditions [25],
the association observed between IDO activity (K/T
ratio) and NFL within cognitively normal elderly

individuals in the current study may further reflect
an association between the extent of inflammation
and the extent of underlying neurodegeneration.
Interestingly, NFL correlated with the KP metabolites
irrespective of the AD-related pathology (NAL)

Fig. 4 Correlations between KP metabolites and Aβ40 (a) and Aβ42 (b) species in all participants. Plasma Aβ40 correlated with the kynurenine to
tryptophan ratio (K/T) and other kynurenine pathway (KP) metabolites, namely kynurenine (KYN), kynurenic acid (KA), anthranilic acid (AA),
quinolinic acid (QA), and picolinic acid (PA) using Pearson’s correlation coefficient. Plasma Aβ42 correlated with the kynurenine to tryptophan (K/
T) ratio and other kynurenine pathway (KP) metabolites, namely kynurenic acid (KA), anthranilic acid (AA), and quinolinic acid (QA) using Pearson’s
correlation coefficient. Log transformed plasma Aβ and KP analyte concentrations have been presented
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Fig. 5 Correlations between KP metabolites and Aβ40 (a) and Aβ42 (b) in participants with low NAL. Plasma Aβ40 correlated with anthranilic acid
(AA) and picolinic acid (PA) using Pearson’s correlation coefficient. Log transformed plasma Aβ and KP analyte concentrations have
been presented

status in cognitively normal elderly individuals that
were at no apparent risk of AD and in those with
preclinical AD, characterised by high NAL. These
observations perhaps reflect previous observations of
elevated NFL not being specifically associated with
NAL pathology but rather being common to the extent of neurodegeneration [7, 8, 45, 46].

For example, Mattsson and colleagues reported no
significant differences in plasma NFL concentrations
between Aβ-negative and Aβ-positive (based on CSF
Aβ42) control individuals [8]. Further, no significant
differences were observed in CSF NFL concentrations between Aβ-negative and Aβ-positive individuals within the control, MCI, or AD groups [45].

Fig. 6 Correlations between KP metabolites and Aβ40 (a) and Aβ42 (b) species in participants with high NAL. Plasma Aβ40 correlated with the
kynurenine to tryptophan ratio (K/T) and other kynurenine pathway (KP) metabolites, namely kynurenine (KYN), kynurenic acid (KA), anthranilic
acid (AA), and quinolinic acid (QA) using Pearson’s correlation coefficient. Plasma Aβ42 correlated with the kynurenine to tryptophan ratio (K/T)
and other kynurenine pathway (KP) metabolites, namely kynurenine (KYN), kynurenic acid (KA), anthranilic acid (AA), and quinolinic acid (QA)
using Pearson’s correlation coefficient. Log transformed plasma Aβ and KP analyte concentrations have been presented
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Additionally, a study within the autosomal dominant
form of AD reported that while the rate of change
of serum NFL was significantly higher in mutation
carriers compared to noncarriers, the positive association observed between the rate of change of serum
NFL and rate of change of brain Aβ deposition did
not reach significance [46]. Findings from our study
are further supported by elevated blood (and CSF)
NFL in primary tauopathies with no Aβ, such as
progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy [7]. Together,
these findings indicate that NFL concentrations are
not driven by NAL and that blood NFL is primarily
a marker of neurodegeneration, which likely resulted
in the observation of NAL status-independent associations between KP metabolites and NFL.
NFL together with neurofilament medium chain and
neurofilament heavy chain constitutes the three neurofilament isoforms. While the neurofilaments are synthesised in the cell body, it has been posited that they are
phosphorylated after transportation to the axon [47]. In
neurodegenerative conditions, the phosphorylated forms
of neurofilaments are observed in the cell body and the
proximal region of the axon, when a disequilibrium in
the phosphorylation-dephosphorylation balance of neurofilaments occurs, as opposed to the distal region of the
axon, in normal conditions [48]. Interestingly, evidence
shows that the KP metabolite, QA, can potentially disrupt the homeostasis of the neural cell cytoskeleton via
aberrant phosphorylation, contributing to aberrant cell
functioning and neurodegeneration [49].
QA has been reported to activate the N-methyl-Daspartate (NMDA) receptor resulting in Ca2+ ion
influx into the cells, activating phosphorylation enzymes and therefore resulting in phosphorylation of
the cytoskeleton components [49]. An acute QA infusion in the striatum of 30-day-old rats stimulated
NFL hyperphosphorylation within 30 min, associated
with cAMP-dependent protein kinase A and protein
kinase Ca2+/calmodulin-dependent protein kinase II
activity, reflecting the vulnerability of both neuronal
and astrocyte cytoskeleton to QA toxicity [49].
While these results show that QA is toxic to the
cytoskeleton and may be associated with neurodegeneration, findings from the current study, most
interestingly, suggest that other KP metabolites upstream to QA are also associated with the disruption
of the neuronal cytoskeleton protein NFL. Whether
the other KP metabolites are associated with plasma
NFL via mechanisms similar to QA are yet to be
investigated.
In contrast to the similar associations observed between KP metabolites and NFL in both low and high
NAL groups, the association between KP metabolites
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and plasma Aβ varied between the two groups,
wherein associations between KP metabolites and
plasma Aβ were nearly absent (particularly with K/T
that reflects IDO activity) in individuals at no apparent risk of AD (or low NAL) but were pronounced
between KP metabolites and plasma Aβ in preclinical
AD, characterised by high NAL. These observations
may be attributed to the vicious nature of the relationship between blood and brain Aβ and KP metabolites in individuals with high NAL, as described in
Fig. 7.
Further, since we observed an interaction effect of NAL
and gender on the KP metabolites previously [14], we also
investigated whether an interaction effect of plasma Aβ and
gender was present on the KP metabolites in the current
study. Interestingly, no interaction effect was observed between plasma Aβ (40 or 42) and gender on KP metabolites.
It is acknowledged that the present study has its
limitations with regard to its relatively modest sample
size. Interestingly, unlike the associations between KP
metabolites and NFL, the association between KP metabolites and the two plasma Aβ species 40 and 42
was distinct between low NAL and high NAL groups.
The association between KP metabolites and plasma
Aβ could be dependent on NAL such that the strong
correlations between plasma Aβ and KP metabolites
in the high NAL group may suggest an association
between Aβ metabolism and inflammation within
amyloid-positive individuals. However, the low Aβ
concentrations in the plasma in the low NAL group
may also contribute to these observations, although
the assay used to measure plasma Aβ in the current
study is an ultra-sensitive assay. Further, while more
sensitive assays may aid increase Aβ measurement accuracy, the current observations also require validation in an independent cohort.

Conclusion
The major findings of the study are that positive correlations exist between KP metabolites and plasma NFL and
Aβ concentrations in elderly individuals, wherein the associations between KP metabolites and plasma NFL are
NAL status independent, while the associations between
KP metabolites and plasma Aβ species (40 and 42) were
NAL status dependent. The peripheral concentrations of
NFL, Aβ, and KP metabolites potentially reflect ongoing
pathological processes in the brain. Plasma NFL levels
reflect axonal cytoskeleton damage [51–53], and plasma
Aβ has been shown to reflect brain Aβ deposition [29,
30], both of which contribute to neurodegeneration,
while increased KP activity is indicative of neuroinflammation [16]. Since observations from the current study
suggest that the association of neurodegeneration and
amyloid pathology with neuroinflammation manifests in
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Fig. 7 Possible mechanisms involved in the association between blood KP metabolites and Aβ in high NAL participants. Elevated blood
kynurenine (KYN), anthranilic (AA), and 3-hydroxykynurenine (3-HK) concentrations in individuals with high neocortical amyloid-β load (NAL) [14]
potentially have increased KYN, AA, and 3-HK concentrations in the brain, given that blood KYN, AA, and 3-HK concentrations account for ~ 60%
of the brain pools of these metabolites, given their permeability to the blood-brain barrier [50]. This increase in the kynurenine pathway (KP)
intermediate substrates could result in increased microglial activation which in turn can result in the secretion of inflammatory signalling
molecules, which further trigger amyloid-β generation and immune responses, resulting in a vicious cycle. Further, immune responses such as
interferon-γ activate indoleamine 2,3-dioxygenase result in increased tryptophan degradation and increased KP metabolites

the periphery, preventing cytoskeleton cytotoxicity by
elevated KP metabolites in the periphery may have
therapeutic potential. Therefore, further studies on the
enzymes that catalyse the production of various KP metabolites and potential KP enzyme inhibitors as potential
therapeutic agents need to be investigated [54].
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